We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CRVS market cap is 319.25M. The company's latest EPS is USD -0.8078 and P/E is -5.17.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.25M | -6.28M | -7.94M | -10.28M | -10.46M |
| Net Income | -5.7M | -4.26M | -40.22M | -12.11M | 15.19M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -43.99M | -43.46M | -42.57M | -28.69M | -30.75M |
| Net Income | -6M | -43.24M | -41.31M | -27.03M | -62.29M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 40.08M | 64.56M | 58.82M | 68.91M | 59.44M |
| Total Liabilities | 6.72M | 13.34M | 46.41M | 36.34M | 10.11M |
| Total Equity | 33.36M | 51.23M | 12.41M | 32.57M | 49.33M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 85.53M | 109.46M | 68.24M | 45.55M | 68.91M |
| Total Liabilities | 13.38M | 12.29M | 12.13M | 6.87M | 36.34M |
| Total Equity | 72.15M | 97.16M | 56.12M | 38.68M | 32.57M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -5.16M | -10.64M | -16.96M | -25.42M | -8.26M |
| Investing | -7k | -17.51M | -21.4M | -27.48M | 4.24M |
| Financing | N/A | 30.37M | 30.42M | 49.03M | 279k |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -34.78M | -36.72M | -27.02M | -23.94M | -25.42M |
| Investing | 44.77M | 21.56M | -23.28M | 15.54M | -27.48M |
| Financing | 1.31M | 62.16M | N/A | 7.86M | 49.03M |
| Market Cap | 319.25M |
| Price to Earnings Ratio | -5.17 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 36.89 |
| Price to Book Ratio | 9.9 |
| Dividend Yield | - |
| Shares Outstanding | 77.11M |
| Average Volume (1 week) | 560.87k |
| Average Volume (1 Month) | 1.23M |
| 52 Week Change | 130.00% |
| 52 Week High | 10.00 |
| 52 Week Low | 1.77 |
| Spread (Intraday) | 0.02 (0.48%) |
| Company Name | Corvus Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.corvuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
